Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

Blood

Volumn 99, Issue 5, 2002, Pages 1659-1665

  Carnemolla, Barbara ^a,b,c   Borsi, Laura ^a,b,c   Balza, Enrica ^a,b,c   Castellani, Patrizia ^a,b,c   Meazza, Raffaella ^a,b,c   Berndt, Alexander ^a,b,c   Ferrini, Silvano ^a,b,c   Kosmehl, Hartwig ^a,b,c   Neri, Dario ^a,b,c   Zardi, Luciano ^a,b,c  

^a UNIVERSITY OF GENOA   (Italy)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; FIBRONECTIN; HYBRID PROTEIN; RECOMBINANT INTERLEUKIN 2;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG TARGETING; EXTRACELLULAR MATRIX; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH; TUMOR MODEL;

EID: 0036493867     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1659     Document Type: Article

References (46)

1. Angiogenesis in cancer, vascular, rheumatoid and other diseases
2. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis
3. Stromal involvement in malignant growth
4. Extracellular matrix modulation of vascular cell behavior
5. Blood vessel formation: What is its molecular basis?
6. Genes expressed in human tumor endothelium
7. Affinity reagents against tumour-associated extracellular molecules and new forming vessels
8. Chemotherapy targeted to vasculature
9. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
10. α v integrins as receptors for tumor targeting by circulating ligands
11. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
12. Phage antibodies with pan-species recognition of the oncofoeta) angiogenesis marker fibronectin ED-B domain
13. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon
14. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors
15. The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis
16. A high-affinity human antibody that targets tumoral blood vessels
17. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
18. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
19. Selective targeting of tumour neo-vasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin
20. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel
21. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment
22. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infraction of solid tumors in mice
23. The IL-2/IL-2 receptor system: A current overview
24. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer
25. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
26. Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab′) with specificity for carcinomas and human IL-2
27. A recombinant single chain antibody interleukin-2 fusion protein
28. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice
29. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
30. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation
31. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody
32. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy
33. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein
34. Targeted cytokines for cancer immunotherapy
35. Antibody-cytokine fusion proteins for the therapy of cancer
36. Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer
37. Mammalian cell expression of dimeric small immune proteins (SIP)
38. Immunotherapy I. Cytokine gene transfer strategies
39. High affinity human IgE receptor (Fc epsilon RI); analysis of functional domains of the alpha-subunit with monoclonal antibodies
40. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma
41. Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to tumor size, nuclear grade, proliferative activity and occurrence of metastasis
42. Phage antibodies: Filamentous phage displaying antibody variable domains
43. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. The identification of adult and embryonic endothelium
44. Immune-inflammatory mechanisms in IFN gamma-mediated anti-tumor activity
45. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure
46. Vascular and interstitial physiology of tumors: Role in cancer detection and treatment